Research Article

Course of Hyperkalemia in Patients on Hemodialysis

Table 2

Risk of predialysis sK+ concentration >5.5 or >6.0 mmol/L at LIDI visits during the 4-week evaluation period following the initial hyperkalemic event.

LIDI visitPredialysis sK+ at randomization (visit 4, day 1) (mmol/L)
<5.5, n = 145.5 to <6.0, n = 376.0 to <6.5, n = 21≥6.5, n = 14

Incidence of predialysis sK + >5.5 mmol/L
Visit 12 (day 36)8/13 (61.5)19/33 (57.6)10/18 (55.6)11/13 (84.6)
Visit 13 (day 43)4/12 (33.3)18/33 (54.5)15/20 (75.0)10/13 (76.9)
Visit 14 (day 50)5/12 (41.7)23/33 (69.7)17/21 (81.0)12/13 (92.3)
Visit 15 (day 57)5/14 (35.7)24/33 (72.7)13/21 (61.9)8/12 (66.7)
Overall22/51 (43.1)84/132 (63.6)55/80 (68.8)41/51 (80.4)

Incidence of predialysis sK + >6.0 mmol/L
Visit 12 (day 36)2/13 (15.4)3/33 (9.1)4/18 (22.2)8/13 (61.5)
Visit 13 (day 43)1/12 (8.3)4/33 (12.1)6/20 (30.0)6/13 (46.2)
Visit 14 (day 50)3/12 (25.0)10/33 (30.3)9/21 (42.9)10/13 (76.9)
Visit 15 (day 57)2/14 (14.3)10/33 (30.3)2/21 (9.5)7/12 (58.3)
Overall8/51 (15.7)27/132 (20.5)21/80 (26.3)31/51 (60.8)

Data are shown as the number (%) of hyperkalemic events. Hyperkalemia was defined as sK+ >5.5 or >6.0 mmol/L after the LIDI. No imputation of missing data was conducted. For each randomization predialysis sK+ subgroup, the probability of whether patients with hyperkalemia will be hyperkalemic (sK+ >5.5 or >6.0 mmol/L) at subsequent visits was calculated as follows: [Number of hyperkalemic events/total number of possible hyperkalemic events based on patients with evaluable data] × 100. LIDI, long interdialytic interval; sK+, serum potassium.